Literature DB >> 1521718

Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.

S Tazuma1, S Hatsushika, N Aihara, H Sagawa, G Yamashita, M Sasaki, H Sasaki, S Mizuno, S Tao, G Kajiyama.   

Abstract

The effects of pravastatin on cholesterol gallstone formation were determined in prairie dogs. We fed 10 prairie dogs 1% cholesterol with or without 0.05% (w/w) pravastatin (n = 5, each) for 4 weeks. In addition, another 5 prairie dogs were fed a standard rodent chow as a control. Only the animals fed 1% cholesterol without pravastatin treatment formed cholesterol gallstones. Gallbladder bile from cholesterol-fed animals contained cholesterol monohydrate crystals, whereas those treated with pravastatin contained no crystal. Furthermore, marked increases in tissue cholesterol levels (serum, liver and bile), and in biliary mucous glycoprotein levels were evident in cholesterol-fed animals, whereas pravastatin treatment normalized these levels. These findings raise the possibility that such inhibitors might have a future role to play in the prevention of cholesterol gallstone formation and/or recurrence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1521718     DOI: 10.1159/000200894

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.

Authors:  F X Caroli-Bosc; P Le Gall; P Pugliese; B Delabre; C Caroli-Bosc; J F Demarquay; J P Delmont; P Rampal; J C Montet
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 3.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

4.  HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells.

Authors:  Jin Lee; Eun Mi Hong; Dong Hee Koh; Min Ho Choi; Hyun Joo Jang; Sea Hyub Kae; Ho Soon Choi
Journal:  Dig Dis Sci       Date:  2009-02-19       Impact factor: 3.199

5.  Statin use and the risk of cholecystectomy in women.

Authors:  Chung-Jyi Tsai; Michael F Leitzmann; Walter C Willett; Edward L Giovannucci
Journal:  Gastroenterology       Date:  2009-01-24       Impact factor: 22.682

6.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.